AstraZeneca
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Employees
- 89.9K
- Market Cap
- $270.3B
- Website
- http://www.astrazeneca.co.uk
- Introduction
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
Korea Osimertinib Real World Evidence Study to Assess Safety and Efficacy - PLUS
Completed
- Conditions
- Carcinoma, Non-Small-Cell Lung
- First Posted Date
- 2019-04-17
- Last Posted Date
- 2024-11-25
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 923
- Registration Number
- NCT03918304
- Locations
- 🇰🇷
Research Site, Seoul, Korea, Republic of
A Clinical Trial to Evaluate AZD7648 Alone and in Combination With Other Anti-cancer Agents in Patients With Advanced Cancers.
- First Posted Date
- 2019-04-09
- Last Posted Date
- 2024-02-06
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 30
- Registration Number
- NCT03907969
- Locations
- 🇬🇧
Research Site, Newcastle upon Tyne, United Kingdom
A Scintigraphy Study of PT010 in COPD Patients
Phase 1
Completed
- Conditions
- Chronic Obstructive Pulmonary Disease
- Interventions
- Drug: BGF-MDI
- First Posted Date
- 2019-04-08
- Last Posted Date
- 2021-02-12
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 18
- Registration Number
- NCT03906045
- Locations
- 🇬🇧
Research Site, Merthyr Tydfil, United Kingdom
Real World Study With Benralizumab in Severe Asthma in Switzerland
Completed
- Conditions
- Severe Eosinophilic Asthma
- First Posted Date
- 2019-04-08
- Last Posted Date
- 2024-02-29
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 79
- Registration Number
- NCT03907137
- Locations
- 🇨🇭
Research Site, Zurich, Switzerland
Prevalence of Asthma and Allergies Among Children in UAE
Completed
- Conditions
- Asthma
- Interventions
- Other: Study questionnaires
- First Posted Date
- 2019-03-18
- Last Posted Date
- 2020-07-17
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 3737
- Registration Number
- NCT03878680
- Locations
- 🇦🇪
Research Site, UMQ, United Arab Emirates
DETERMINE-preserved - Dapagliflozin Effect on Exercise Capacity Using a 6-minute Walk Test in Patients With Heart Failure With Preserved Ejection Fraction
Phase 3
Completed
- Conditions
- Heart Failure With Preserved Ejection Fraction (HFpEF)
- Interventions
- Other: Placebo
- First Posted Date
- 2019-03-15
- Last Posted Date
- 2021-11-17
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 504
- Registration Number
- NCT03877224
- Locations
- 🇸🇪
Research Site, Umeå, Sweden
DETERMINE-reduced - Dapagliflozin Effect on Exercise Capacity Using a 6-minute Walk Test in Patients With Heart Failure With Reduced Ejection Fraction
Phase 3
Completed
- Conditions
- Heart Failure With Reduced Ejection Fraction (HFrEF)
- Interventions
- Other: Placebo
- First Posted Date
- 2019-03-15
- Last Posted Date
- 2021-05-05
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 313
- Registration Number
- NCT03877237
- Locations
- 🇸🇪
Research Site, Umeå, Sweden
Durvalumab or Placebo in Combination With Gemcitabine/Cisplatin in Patients With 1st Line Advanced Biliary Tract Cancer (TOPAZ-1)
Phase 3
Active, not recruiting
- Conditions
- Biliary Tract Neoplasms
- Interventions
- Drug: Placebo
- First Posted Date
- 2019-03-14
- Last Posted Date
- 2025-02-25
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 810
- Registration Number
- NCT03875235
- Locations
- 🇬🇧
Research Site, Sheffield, United Kingdom
SABINA INTERNATIONAL
Completed
- Conditions
- Asthma
- First Posted Date
- 2019-02-27
- Last Posted Date
- 2021-02-11
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 8617
- Registration Number
- NCT03857178
- Locations
- 🇦🇷
Research Site, San Salvador, Argentina
Osimertinib Study in Indian Patients
- First Posted Date
- 2019-02-25
- Last Posted Date
- 2021-06-03
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 60
- Registration Number
- NCT03853551
- Locations
- 🇮🇳
Research Site, New Delhi, India
© Copyright 2025. All Rights Reserved by MedPath